From Sept to December the O/S increased approx 5.5 Million shares. 55 trading days in that time period shows the company increasing the O/S 100,000 shares a day on a lightly traded stock. Is this a possible reason for the price drop.
I am not the one who states they don't need to partner to do our own phase 3 trials.
They NEED a partner. The sooner the better. Stating anything else is nonsense. It shouldn't be a problem if the drugs have the potential we think they do.